214980-19-5

Basic information

• Product Name: 4-(benzyloxycarbonylamino)phenyl-acetaldehyde
• Synonyms: 4-(benzyloxycarbonylamino)phenyl-acetaldehyde
• CAS NO: 214980-19-5
• Molecular Weight: 269.3
• Mol File: 214980-19-5.mol

Chemical Properties

• CAS DataBase Reference: 4-(benzyloxycarbonylamino)phenyl-acetaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxycarbonylamino)phenyl-acetaldehyde(214980-19-5)
• EPA Substance Registry System: 4-(benzyloxycarbonylamino)phenyl-acetaldehyde(214980-19-5)

Safety Data

• Hazardous Substances Data: 214980-19-5(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 214980-03-7 2-(4-(benzyloxycarbonylamino)phenyl)ethyl alcohol 

Downstream Products

• 934270-98-1 6-((4-aminophenyl)ethylamino)-2-cyanobenzothiazole 
• 934270-96-9 6-((4-benzyloxycarbonylaminophenyl)ethylamino)-2-cyanobenzothiazole 

Relevant articles and documents

New class of bioluminogenic probe based on bioluminescent enzyme-induced electron transfer: BioLeT

Bioluminescence imaging (BLI) has advantages for investigating biological phenomena in deep tissues of living animals, but few design strategies are available for functional bioluminescent substrates. We propose a new design strategy (designated as bioluminescent enzyme-induced electron transfer: BioLeT) for luciferin-based bioluminescence probes. Luminescence measurements of a series of aminoluciferin derivatives confirmed that bioluminescence can be controlled by means of BioLeT. Based on this concept, we developed bioluminescence probes for nitric oxide that enabled quantitative and sensitive detection even in vivo. Our design strategy should be applicable to develop a wide range of practically useful bioluminogenic probes.

Novel luciferin derivatives

A compound represented by the following general formula (I) or a salt thereof: [wherein R1 and R2 represent hydrogen atom, a C1-6 alkyl group, or a group represented by the following formula (A): [wherein X1 and X2 represent hydrogen atom, or a group represented as —N(R3)(R4) (R3 and R4 represent hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, or a C1-6 alkyloxycarbonyl group); and n represents an integer of 1 to 6], provided that R1 and R2 do not simultaneously represent hydrogen atom), which is a novel luciferin derivative that serves as a luciferase substrate.

4,1-benzoxazepines, their analogues, and their use as somatostatin agonists

The present invention provides a compound of the formula: wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R1is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R2is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, —CON(Ra)—, —N(Ra)CO—, —N(Rb)CON(Rc)—, —N(Rd)COO—, —N(Re)SO2—, —COO—, —N(Rf)—, —O—, —S— —SO—, —SO2—, (in which Ra, Rb, Rc, Rd, Reand Rfare respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group; ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R2; X is two hydrogen atoms, an oxygen atom or a sulfur atom;is a single bond or a double bond, and Y is a nitrogen atom whenis a double bond, or an oxygen atom, —N(R4)— (in which R4is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O)n(in which n is 0, 1 or 2) whenis a single bond, or a salt thereof, which have somatostatin receptor agonistic action.